We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma
Read MoreHide Full Article
Amgen, Inc. (AMGN - Free Report) announced that the FDA has approved its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.
Xgeva is currently approved for the prevention of skeletal-related events (SREs) in solid tumors in patients with bone metastases. With the latest FDA approval, the label of Xgeva will be expanded to include patients with multiple myeloma.
The FDA decision comes earlier than the PDUFA date of Feb 2, 2018. A similar regulatory application is also under review in the EU.
In the past year, Amgen’s shares have returned 13.8% in contrast to 1.7% decrease registered by the industry.
The FDA approval was based on safety and efficacy from the pivotal phase III '482 study, which enrolled 1,718 patients. The head-to-head study, which compared Xgeva to Novartis AG’s (NVS - Free Report) Zometa (zoledronic acid), met the primary endpoint of non-inferiority of the drugs in delaying the time to first on-study SRE in patients with multiple myeloma.
Bone complications in patients with multiple myeloma can be quite damaging. Until now, bisphosphonates were the only treatment option available for bone protection in multiple myeloma patients. However, bisphosphonates may cause renal toxicity and lead to renal impairment. Xgeva, which is not cleared through the kidneys, offers a better treatment option for such patients.
Xgeva is key revenue driver for Amgen and generated revenues of $1.18 billion in the first nine months of 2017, up 3% year over year. We expect approval for the expanded patient population to help in further boosting sales of the drug.
Vertex’s stock has returned 87.9% in the past year while earnings estimates for 2018 have gone up by almost 3% in the past 30 days.
Earnings estimates for Exelixis have moved north by 1.4% in the past 30 days while the stock price has increased 79.9% in the past year.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Amgen's (AMGN) Xgeva Gets FDA Approval for Multiple Myeloma
Amgen, Inc. (AMGN - Free Report) announced that the FDA has approved its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.
Xgeva is currently approved for the prevention of skeletal-related events (SREs) in solid tumors in patients with bone metastases. With the latest FDA approval, the label of Xgeva will be expanded to include patients with multiple myeloma.
The FDA decision comes earlier than the PDUFA date of Feb 2, 2018. A similar regulatory application is also under review in the EU.
In the past year, Amgen’s shares have returned 13.8% in contrast to 1.7% decrease registered by the industry.
The FDA approval was based on safety and efficacy from the pivotal phase III '482 study, which enrolled 1,718 patients. The head-to-head study, which compared Xgeva to Novartis AG’s (NVS - Free Report) Zometa (zoledronic acid), met the primary endpoint of non-inferiority of the drugs in delaying the time to first on-study SRE in patients with multiple myeloma.
Bone complications in patients with multiple myeloma can be quite damaging. Until now, bisphosphonates were the only treatment option available for bone protection in multiple myeloma patients. However, bisphosphonates may cause renal toxicity and lead to renal impairment. Xgeva, which is not cleared through the kidneys, offers a better treatment option for such patients.
Xgeva is key revenue driver for Amgen and generated revenues of $1.18 billion in the first nine months of 2017, up 3% year over year. We expect approval for the expanded patient population to help in further boosting sales of the drug.
Amgen carries a Zacks Rank #3 (Hold).
Better-ranked biotech stocks are Vertex Pharmaceuticals Inc. (VRTX - Free Report) and Exelixis, Inc. (EXEL - Free Report) , both with a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Vertex’s stock has returned 87.9% in the past year while earnings estimates for 2018 have gone up by almost 3% in the past 30 days.
Earnings estimates for Exelixis have moved north by 1.4% in the past 30 days while the stock price has increased 79.9% in the past year.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>